ERBB2 and neoplasm: Currently, the conventional clinicopathologic indicators, including tumor size, lymph node metastasis, TNM stage, and cellular biomarkers (ER, PR, HER-2 status and Ki-67 index) of tumor biopsy, are still the gold standard for the risk stratification and subsequent formulating of therapeutic scheme.